1
|
Asano M, Umezu T, Katagiri S, Kobayashi C, Tauchi T, Gotoh M, Ando K, Okabe S, Ohyashiki JH, Ohyashiki K. Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors. Int J Hematol 2017; 105:419-422. [PMID: 28197964 DOI: 10.1007/s12185-017-2199-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Revised: 02/07/2017] [Accepted: 02/07/2017] [Indexed: 11/27/2022]
Abstract
We analyzed the exosomal miRNA from peripheral blood from CML patients with musculoskeletal pain after stopping tyrosine kinase inhibitors to identify possible factors related to this manifestation. Exosomal miRNA profiling using TaqMan low-density array revealed that exosomal miR-140-3p was significantly elevated in CML patients showing musculoskeletal pain, when compared to those without such pain (P = 0.0336) or healthy individuals (P = 0.0022). All five CML patients with musculoskeletal pain and increased exosomal miR-140-3p levels sustained deep molecular responses: four of them achieved symptom relief and a significant decrease in exosomal miR-140-3p levels was evident. Because exosomal miR-140-3p is considered to have an inflammation-associated biological function in airway smooth muscle cells and targets Myomarker muscle-specific transmembrane protein, it appears that its overexpression in circulating exosomal miR-140-3p may have some role in the mechanism underlying self-limited musculoskeletal pain.
Collapse
Affiliation(s)
- Michiyo Asano
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan.,Department of Hematology, Erasmus Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands
| | - Tomohiro Umezu
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan.,Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University, 160-0023, Tokyo, Japan
| | - Seiichiro Katagiri
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan
| | - Chiaki Kobayashi
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan.,Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University, 160-0023, Tokyo, Japan
| | - Tetsuzo Tauchi
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan
| | - Moritaka Gotoh
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan
| | - Keiko Ando
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan
| | - Seiichi Okabe
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan
| | - Junko H Ohyashiki
- Department of Molecular Oncology, Institute of Medical Science, Tokyo Medical University, 160-0023, Tokyo, Japan
| | - Kazuma Ohyashiki
- Department of Hematology, Tokyo Medical University, 160-0023, Tokyo, Japan.
| |
Collapse
|